The study results suggest that in Alzheimer disease, plasma P-tau217 becomes abnormal before tau-PET and that plasma P-tau217 may be considered as an early Alzheimer disease biomarker. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.